A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia
A study for patients with Leukemia using study drug acalabrutinib
Sponsor: Acerta Pharma
Enrolling: Male and Female Patients
IRB Number: AAAQ4711
U.S. Govt. ID: NCT02477696
Contact: Ryan Shelton: 212-304-5485 / rs3323@cumc.columbia.edu
Additional Study Information: The purpose of this study, which involves research, is to determine if an experimental drug: acalabrutinib is safe and effective in the treatment of this patients with High Risk Chronic Lymphocytic Leukemia (CLL). Acalabrutinib is an investigational drug, which means that it is still being tested in people and has not been approved by government agencies in any countries. Acalabrutinib has been tested previously in more than 800 humans and has been well tolerated. Acalabrutinib is administered as an oral capsule. To be able to participate, you will need to be more than 18 years old and must have CLL that has already been treated. In addition, your CLL must have gotten worse while on your previous treatment (or after stopping your previous treatment) in order for you to be eligible for this study.
This study is closed
Investigator
Nicole Lamanna, MD
Do You Qualify?
Have you been diagnosed with Chronic Lymphocytic Leukemia (CLL)? Yes No
Does your CLL require therapy because it is growing and is causing medical problems, such as fatigue, fever or infections? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Ryan Shelton
rs3323@cumc.columbia.edu
212-304-5485